|
|
 |
|
Viewing report
|
|
|
|
Multi-Client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in the Philippines
Frost & Sullivan, Dec 2009, Pages: 58
This research service aims to provide an update on the epidemiology of Hepatitis C, including the prevalence and incidence, Market Engineering measurements, and government initiatives. It also covers patient source, load, and forecasts, while also outlining the key treaters involved. Current diagnostic methods are presented, followed by treatment regimens, their cost, and upcoming product launches. Clinical trials highlighting research into new treatments are also provided, along with an analysis of the pipeline. Additionally, there is a competitive analysis which includes the market structure, major participants, and future trends. This service covers the Hepatitis C therapeutics market in the Philippines
This Frost & Sullivan research service titled Multi-Client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in the Philippines provides an overview of the Hepatitis C market, government initiatives, patient load and classification, patient forecasts, treatment regimens, product launches, and challenges faced by physicians.
This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Services program. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services program ensures that you and your Growth Team™ are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth.
Market Overview
Imminent Launch of Small-molecule Antiviral Drugs Poised to Improve Treatment Success Rates for Hepatitis C Patients
Efforts to raise disease awareness have increased the number of diagnosed cases and expanded the patient base available for hepatitis C treatment in the Philippines. Improved screening and detection efforts by the Red Cross and better awareness among the population have been largely responsible for the rise in the number of diagnosed cases. These campaigns have encouraged people, mostly from urban areas, to opt for physical examinations that enable the detection of hepatitis C. Physicians and key opinion leaders (KOLs) believe that the diagnosis rate will increase gradually, after the Philippine Government officially implements its Hepatitis C program to spread awareness of the disease in the country. In the future, refined versions of current hepatitis C virus (HCV) drugs, oral formulations of small molecule inhibitors, and the new drug class known as protease inhibitors are expected to improve treatment success rates for patients and take the market forward. 'The highest patient group for Hepatitis C in the Philippines is injecting drug users who share needles both for narcotic and therapeutic purposes,' notes the analyst of this research service. 'Another patient group at risk for Hepatitis C is those who receive blood products that may not have been screened properly; the latter is more of a concern in rural rather than urban areas in the country.'
Although diagnosis rates have improved, there are impediments deterring market progression. Treatment of hepatitis C is restrained by the high cost of medication for patients who do not have health insurance. When combined with known side effects, which include flu-like symptoms, neuropsychiatric disorders, and autoimmune syndromes, results in lowered patient compliance. The Philippines does not reimburse treatment for Hepatitis C, and medical insurance companies do not allow reimbursement for these costs. In the Philippines, the cost of treatments is notably higher compared to other Asian countries and patients struggle to shoulder the cost of treatment. It is challenging for both urban and rural patients to afford the costly treatment for hepatitis C. In addition, the intravenous mode of administration is viewed as inconvenient by some patients, which leads to lower compliance. 'As far as treatment modes are concerned, small molecule antivirals are dominating the pipeline since they have met with success in the treatment of other viral infections such as hepatitis B and HIV,' says the analyst. 'Several strategies are being explored in clinical trials, including add-on therapy to the current standard of care, interferon replacement, and ribavirin replacement.'
To circumvent the bottlenecks in this market, companies must offer treatment options that expedite efficiency, have fewer side effects, and are reasonably priced. Patients should be made aware of their disease status early and encouraged to remain compliant. Furthermore, incentives must be provided to ensure compliance to HCV treatment, amplifying the likelihood of future compliance, especially for improved treatments. To educate at-risk patients, public and private organizations, including pharmaceutical companies, must step up awareness efforts. Greater information outreach will help patients obtain the right mode of treatment and ultimately stem the onslaught of HCV in the Philippines.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in Hong Kong
Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in Singapore
Hepatitis C Therapeutics Market—Thailand
Multi-client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in South Korea
Multi-client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in Malaysia
Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in India
Hepatitis C Therapeutics Market – Taiwan
Multi Client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in China
Hepatitis C Virus and Therapeutics - Global Strategic Business Report
R&D Trends: Hepatitis C
|
|
|
|
